PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Sold by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. decreased its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 4.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 985,942 shares of the company's stock after selling 45,785 shares during the period. T. Rowe Price Investment Management Inc. owned 1.89% of PROCEPT BioRobotics worth $79,389,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Raleigh Capital Management Inc. bought a new position in shares of PROCEPT BioRobotics in the fourth quarter valued at about $32,000. Thematics Asset Management acquired a new stake in PROCEPT BioRobotics in the fourth quarter valued at approximately $46,000. Signaturefd LLC raised its position in PROCEPT BioRobotics by 26.7% in the fourth quarter. Signaturefd LLC now owns 689 shares of the company's stock valued at $55,000 after purchasing an additional 145 shares during the last quarter. IFP Advisors Inc bought a new stake in PROCEPT BioRobotics during the 4th quarter worth approximately $58,000. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of PROCEPT BioRobotics during the third quarter worth about $64,000. Institutional investors and hedge funds own 89.46% of the company's stock.

Insider Buying and Selling

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 733 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the sale, the chief financial officer now directly owns 107,991 shares of the company's stock, valued at $6,161,966.46. The trade was a 0.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the sale, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. This trade represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,455 shares of company stock worth $368,322. 17.40% of the stock is owned by corporate insiders.

PROCEPT BioRobotics Stock Down 0.8 %

PROCEPT BioRobotics stock traded down $0.43 on Thursday, hitting $53.56. 252,076 shares of the stock traded hands, compared to its average volume of 810,697. PROCEPT BioRobotics Co. has a 1 year low of $47.04 and a 1 year high of $103.81. The business's fifty day simple moving average is $57.13 and its 200 day simple moving average is $73.61. The firm has a market cap of $2.96 billion, a P/E ratio of -27.50 and a beta of 1.09. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. The firm had revenue of $69.16 million for the quarter, compared to the consensus estimate of $65.39 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The company's quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.51) earnings per share. As a group, sell-side analysts forecast that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Bank of America dropped their price objective on PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. Truist Financial dropped their target price on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Finally, Morgan Stanley lowered their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $90.00.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).